Search Within

Brian Zeglis

Formats
  1. Journal Article (86)
  2. Meeting Abstract (18)
  3. Review (10)
  4. Book Section (5)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. GSK Faculty (74)
  2. Radiochemistry and Imaging Sciences Service (74)
  3. Radiology, Department of (74)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (70)
  5. Center for Pancreatic Cancer Research (69)
  6. Sloan Kettering Institute Postdocs (54)

More Groups

People
  1. Jason Lewis (69)
  2. Outi Keinanen (18)
  3. Samantha Delaney (12)
  4. Thomas Reiner (12)
  5. Sai Kiran Sharma (11)
  6. Samantha Sarrett (11)

More People

Years
  1. 2025 (3)
  2. 2024 (11)
  3. 2023 (10)
  4. 2022 (9)
  5. 2021 (7)
  6. 2020 (10)

More Years

Publications
  1. Journal of Nuclear Medicine (14)
  2. Bioconjugate Chemistry (12)
  3. Journal of Labelled Compounds and Radiopharmaceuticals (11)
  4. Molecular Pharmaceutics (11)
  5. Nuclear Medicine and Biology (7)
  6. Journal of Visualized Experiments (5)

More Publications

Publishers
  1. American Chemical Society (33)
  2. Society of Nuclear Medicine (14)
  3. Springer (13)
  4. Wiley Blackwell (13)
  5. Elsevier Science Inc. (7)
  6. American Association for Cancer Research (6)

More Publishers

Results (121)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DiPODS: A reagent for site-specific bioconjugation via the irreversible rebridging of disulfide linkages
    Journal Article

    Khozeimeh Sarbisheh, E.; Dewaele-Le Roi, G.; Shannon, W. E.; Tan, S.; Xu, Y.; Zeglis, B. M.; Price, E. W.
    Bioconjugate Chemistry (2020)

    Fulltext@MSK | Save
  • Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
    Journal Article

    Keinänen, O.; Fung, K.; Brennan, J. M.; Zia, N.; Harris, M.; van Dam, E.; Biggin, C.; Hedt, A.; Stoner, J.; Donnelly, P. S.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2020)

    Fulltext@MSK | Save
  • A molecularly targeted intraoperative near-infrared fluorescence imaging agent for high-grade serous ovarian cancer
    Journal Article

    Fung, K.; Sharma, S. K.; Keinänen, O.; Long Roche, K.; Lewis, J. S.; Zeglis, B. M.
    Molecular Pharmaceutics (2020)

    Fulltext@MSK | Save
  • Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted (89)Zr-pertuzumab PET/CT
    Journal Article

    Ulaner, G. A.; Carrasquillo, J. A.; Riedl, C. C.; Yeh, R.; Hatzoglou, V.; Ross, D. S.; Jhaveri, K.; Chandarlapaty, S.; Hyman, D. M.; Zeglis, B. M.; more...
    Radiology (2020)

    Fulltext@MSK | Save
  • Removal of Fc glycans from [(89)Zr]Zr-DFO-anti-CD8 prevents peripheral depletion of CD8(+) T cells
    Journal Article

    White, J. M.; Keinänen, O. M.; Cook, B. E.; Zeglis, B. M.; Gibson, H. M.; Viola, N. T.
    Molecular Pharmaceutics (2020)

    Fulltext@MSK | Save
  • Targeted brain tumor radiotherapy using an auger emitter
    Journal Article

    Pirovano, G.; Jannetti, S. A.; Carter, L. M.; Sadique, A.; Kossatz, S.; Guru, N.; De Souza França, P. D.; Maeda, M.; Zeglis, B. M.; Lewis, J. S.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • (89)Zr-labeled AR20.5: A MUC1-targeting ImmunoPET probe
    Journal Article

    Fung, K.; Vivier, D.; Keinänen, O.; Sarbisheh, E. K.; Price, E. W.; Zeglis, B. M.
    Molecules (2020)

    Fulltext@MSK | Save
  • Poly(ADP-ribose)polymerase (PARP) inhibitors and radiation therapy
    Review

    Jannetti, S. A.; Zeglis, B. M.; Zalutsky, M. R.; Reiner, T.
    Frontiers in Pharmacology (2020)

    Fulltext@MSK | Save
  • Manipulating the in vivo behaviour of (68)Ga with tris(hydroxypyridinone) chelators: Pretargeting and blood clearance
    Journal Article

    Imberti, C.; Adumeau, P.; Blower, J. E.; Al Salemee, F.; Torres, J. B.; Lewis, J. S.; Zeglis, B. M.; Terry, S. Y. A.; Blower, P. J.
    International Journal of Molecular Sciences (2020)

    Fulltext@MSK | Save
  • The influence of glycans-specific bioconjugation on the FcγRI binding and in vivo performance of (89)Zr-DFO-pertuzumab
    Journal Article

    Vivier, D.; Fung, K.; Rodriguez, C.; Adumeau, P.; Ulaner, G. A.; Lewis, J. S.; Sharma, S. K.; Zeglis, B. M.
    Theranostics (2020)

    Fulltext@MSK | Save